Premium
Erratum: Effect of GLP ‐1 receptor agonist treatment on body weight in obese antipsychotic‐treated patients with schizophrenia: A randomized, placebo‐controlled trial
Author(s) -
Ebdrup Bjørn H.,
Broberg Brian V.,
Ishøy Pelle L.,
Bak Nikolaj,
Andersen Ulrik B.,
Jørgensen Niklas R.,
Holst Jens J.,
Knop Filip K.,
Glenthøj Birte Y.
Publication year - 2018
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/dom.13204
Subject(s) - exenatide , placebo , medicine , type 2 diabetes , antipsychotic , agonist , glucagon like peptide 1 receptor , weight loss , obesity , schizophrenia (object oriented programming) , endocrinology , diabetes mellitus , receptor , psychiatry , alternative medicine , pathology
Aims Schizophrenia is associated with cardiovascular co-morbidity and a reduced life-expectancy of up to 20 years. Antipsychotics are dopamine D2 receptor antagonists and the standard of medical care in schizophrenia, but the drugs are associated with severe metabolic side effects like obesity and diabetes. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are registered for treatment of both obesity and type 2 diabetes. We investigated metabolic effects of the GLP-1RA, exenatide once-weekly, in non-diabetic, antipsychotic-treated, obese patients with schizophrenia. Material and Methods Antipsychotic-treated, obese, non-diabetic, schizophrenia spectrum patients were randomized to double-blinded adjunctive treatment with once-weekly subcutaneous exenatide (n = 23) or placebo (n = 22) injections for three months. The primary outcome was body weight loss after treatment and repeated measures analysis of variance was used as statistical analysis. Results Between March 2013 and June 2015, 40 patients completed the trial. At baseline, the mean body weight was 118.3 ± 16.0 kg in the exenatide group and 111.7 ± 18.0 kg in the placebo group, with no group differences (P = 0.23). The exenatide and placebo groups experienced significant (P = 0.004), however, similar (P = 0.98) weight losses of 2.24 ± 3.3 kg and 2.23 ± 4.4 kg, respectively, after three months of treatment. Conclusions Treatment with exenatide once-weekly did not promote weight loss in obese, antipsychotic-treated patients with schizophrenia compared to placebo. Our results could suggest that the body weight-lowering effect of GLP-1RAs involves dopaminergic signaling, but blockade of other receptor systems may also play a role. Nevertheless, anti-obesity regimens effective in the general population may not be readily implemented in antipsychotic-treated patients with schizophrenia ClinicalTrials.gov identifier: NCT01794429